Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
NIH staff guidance on coronavirus (NIH Only)
The National Institute of Neurological Disorders and Stroke conducts and supports research to understand lipid storage diseases such as acid lipase deficiency and to develop treatments targeting disease mechanisms. Research being conducted through the Lysosomal Diseases Network is collecting longitudinal data that can be used to improve the care and treatment of people with lysosomal acid lipsae deficiency. Additional research studies hope to identify biomarkers (signs that may indicate risk of a disease and improve diagnosis) for the lipid storage diseases that will speed the development of novel therapeutics for these disorders.
The National Institute of Neurological Disorders and Stroke conducts and supports research to understand lipid storage diseases such as acid lipase deficiency and to develop treatments targeting disease mechanisms. Research being conducted through the Lysosomal Diseases Network is collecting longitudinal data that can be used to improve the care and treatment of people with lysosomal acid lipsae deficiency. Additional research studies hope to identify biomarkers (signs that may indicate risk of a disease and improve diagnosis) for the lipid storage diseases that will speed the development of novel therapeutics for these disorders.
The National Institute of Neurological Disorders and Stroke conducts and supports research to understand lipid storage diseases such as acid lipase deficiency and to develop treatments targeting disease mechanisms. Research being conducted through the Lysosomal Diseases Network is collecting longitudinal data that can be used to improve the care and treatment of people with lysosomal acid lipsae deficiency. Additional research studies hope to identify biomarkers (signs that may indicate risk of a disease and improve diagnosis) for the lipid storage diseases that will speed the development of novel therapeutics for these disorders.
Acid lipase disease or deficiency occurs when the enzyme needed to break down certain fats that are normally digested by the body is lacking or missing, resulting in the toxic buildup of these fats in the body’s cells and tissues. These fatty substances, called lipids, include fatty acids, oils, and cholesterol. Two rare lipid storage diseases are caused by the deficiency of the enzyme lysosomal acid lipase, both of which are interited and affect males and females
Acid lipase disease or deficiency occurs when the enzyme needed to break down certain fats that are normally digested by the body is lacking or missing, resulting in the toxic buildup of these fats in the body’s cells and tissues. These fatty substances, called lipids, include fatty acids, oils, and cholesterol. Two rare lipid storage diseases are caused by the deficiency of the enzyme lysosomal acid lipase, both of which are interited and affect males and females
Enzyme replacement therapy for both Wolman's and cholesteryl ester storage disease is currently under investigation. Certain drugs may be given to help with adrenal gland production, and children may need to be fed intravenously. Individuals with CESD may benefit from a low cholesterol diet.
Enzyme replacement therapy for both Wolman's and cholesteryl ester storage disease is currently under investigation. Certain drugs may be given to help with adrenal gland production, and children may need to be fed intravenously. Individuals with CESD may benefit from a low cholesterol diet.
Acid lipase disease or deficiency occurs when the enzyme needed to break down certain fats that are normally digested by the body is lacking or missing, resulting in the toxic buildup of these fats in the body’s cells and tissues. These fatty substances, called lipids, include fatty acids, oils, and cholesterol. Two rare lipid storage diseases are caused by the deficiency of the enzyme lysosomal acid lipase, both of which are interited and affect males and females
Enzyme replacement therapy for both Wolman's and cholesteryl ester storage disease is currently under investigation. Certain drugs may be given to help with adrenal gland production, and children may need to be fed intravenously. Individuals with CESD may benefit from a low cholesterol diet.
Wolman’s disease is usually fatal by age 1. The onset and course of cholesteryl ester storage disease varies, and individuals may live into adulthood.
Wolman’s disease is usually fatal by age 1. The onset and course of cholesteryl ester storage disease varies, and individuals may live into adulthood.
Wolman’s disease is usually fatal by age 1. The onset and course of cholesteryl ester storage disease varies, and individuals may live into adulthood.
Acid lipase disease or deficiency occurs when the enzyme needed to break down certain fats that are normally digested by the body is lacking or missing, resulting in the toxic buildup of these fats in the body’s cells and tissues. These fatty substances, called lipids, include fatty acids, oils, and cholesterol. Two rare lipid storage diseases are caused by the deficiency of the enzyme lysosomal acid lipase, both of which are interited and affect males and females
Enzyme replacement therapy for both Wolman's and cholesteryl ester storage disease is currently under investigation. Certain drugs may be given to help with adrenal gland production, and children may need to be fed intravenously. Individuals with CESD may benefit from a low cholesterol diet.
Wolman’s disease is usually fatal by age 1. The onset and course of cholesteryl ester storage disease varies, and individuals may live into adulthood.
The National Institute of Neurological Disorders and Stroke conducts and supports research to understand lipid storage diseases such as acid lipase deficiency and to develop treatments targeting disease mechanisms. Research being conducted through the Lysosomal Diseases Network is collecting longitudinal data that can be used to improve the care and treatment of people with lysosomal acid lipsae deficiency. Additional research studies hope to identify biomarkers (signs that may indicate risk of a disease and improve diagnosis) for the lipid storage diseases that will speed the development of novel therapeutics for these disorders.
No organizations listed at this time
No organizations listed at this time